Overview

Research Study to Compare Semaglutide Tablets With Empagliflozin Tablets Taken Once Daily in People With Type 2 Diabetes and Obesity

Status:
Not yet recruiting

Trial end date:
2025-08-29

Target enrollment:

Participant gender:

Summary

This study compares the medicines semaglutide and empagliflozin in people with newly diagnosed type 2 diabetes and obesity. The study will look mainly at how well the blood sugar and body weight are controlled when participants are taking the study medicine. Participants will either get semaglutide tablets or empagliflozin tablets. Which treatment participants get is decided by chance. Participants will get one tablet per day for 2 years. The study will last for about 2 years and 8 weeks.

Phase:

Phase 3

Details

Lead Sponsor:

Novo Nordisk A/S

Treatments:

Empagliflozin